Join UNITY Biotechnology in-person or virtually for its 2024 Investor and Analyst Day, featuring presentations from prominent ophthalmology key opinion leaders and company management, including:

• Robert Bhisitkul, MD, PhD – UCSF School of Medicine
• Arshad Khanani, MD, MA, FASRS – Sierra Eye Associates, University of Nevada Reno School of Medicine
• Dante Pieramici, MD – California Retina Consultants

The event will focus on the ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Twenty-four-week safety and efficacy data are expected in the first quarter of 2025 and 36-week data are expected in the second quarter of 2025. A KOL fireside chat will address the evolving therapeutic landscape and the potential of UBX1325 to address unmet need in DME.

A live question and answer session will follow the formal presentations.